In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Editorial Advisory Board
 

Brian Chapman

ZS Associates, Partner

Brian Chapman is a partner with ZS in the Zurich office and leader of ZS’ Global Medtech Consulting Practice.  During his time at ZS, he has worked with medical device and diagnostics companies on a range of sales and marketing issues such as organizational design, forecasting, channel design, new product launch strategy, pricing, opportunity assessment, value proposition development and sales force effectiveness.  Mr. Chapman has lived and worked in the US as well as Europe and also has spent several years working in Asia on consulting and training engagements with multinational pharmaceutical, device and diagnostics companies. Mr. Chapman joined ZS in 2004. Prior to ZS, he worked in the chemical industry in a variety of technical and commercial roles.  He has an MBA with distinction from the Ross School of Business at the University of Michigan and a BS in Chemical Engineering from Michigan Technological University.

 

Benjamin Comer

PwC, Senior Manager, Health Research Institute

Ben Comer is a writer and reporter with nine years’ experience covering the biopharmaceutical and medical device industries. He is currently a member of PwC's Health Research Institute, and has worked as a licensed pharmaceutical technician and drug compounding specialist. Mr. Comer has particular expertise in drug pricing and commercial strategy, regulatory and compliance issues, and health policy and social issues.

 

Don Creighton

Huron Consulting Group, Managing Director, Life Sciences Practice

Don Creighton joined Huron Consulting in 2018. Previously he led US and European operations for ICON's Consulting Practice, overseeing staff in four locations. He has 20 years’ health care experience in industry, consulting and scientific research.  As a global oncology market access lead at Pfizer, he launched the first lung cancer drug with a companion diagnostic. Mr. Creighton leverages his unique background in both pricing and market access strategy and health care policy development to build trusted partnerships with clients to foster strategic and professional development.


Deborah Dunsire, MD

XTuit Pharmaceuticals, President & CEO

Deborah Dunsire is president and CEO of XTuit Pharmaceuticals.  Previously, she was CEO of Forum Pharmaceuticals and Millennium Pharmaceuticals. After Millennium was acquired by Takeda Pharmaceuticals in 2008, Dr. Dunsire joined the board of Takeda in Japan, becoming the first female board member in the company's 284-year history. She spent 17 years at Novartis in South Africa, Switzerland and the US. For 11 years, she led the Novartis Oncology business in North America, developing and launching a number of transformational cancer medicines notably Gleevec, the first targeted cancer therapy. Dr. Dunsire has been a board member of Allergan Pharmaceuticals for nine years including during the landmark hostile takeover approach from Valeant. She is a current board member of Ultragenyx Pharmaceuticals. A physician, Dr. Dunsire trained at University of the Witwatersrand in Johannesburg, South Africa.



Les Funtleyder

E Squared Capital Management, Health Care Portfolio Manager

Les Funtleyder is a health care portfolio manager at E Squared Capital Management where he is responsible for conducting fundamental and valuation analysis of public and private companies within the health care industry. He is also a professor of public health at Columbia University and a senior advisor to McKinsey & Co. Prior to E Squared Mr. Funtleyder was the director of strategic investments for Opko Health. Earlier, he was a health care strategist and portfolio manager for the Miller Tabak Health Care Transformation Fund. He joined Miller Tabak after managing a health care portfolio for Provident Advisors, a hedge fund in Minneapolis, MN.  Before joining Provident, he worked as a medical device analyst at UBS Warburg. He also covered biotechnology stocks at Bigelow and Company. Mr. Funtleyder wrote Health-Care Investing: Profiting from the New World of Pharma, Biotech, and Health-Care Services (McGraw-Hill), which bridges the gap between health reform, innovation and investing. He earned his Masters of Public Health from Columbia University Mailman School of Public Health, and studied English and Economics at Tulane University.


 

Linda Harpole, MD

SAS, CMO

Linda Harpole joined SAS in February 2017 as chief medical officer in health and life sciences.  She is a board-certified internist with over 20 years of academic and pharmaceutical industry research experience, with expertise in real-world evidence, pharmaco-economics, patient-reported outcomes and health system interventions across a breadth of therapeutic areas.  Prior to joining SAS, Dr. Harpole worked both at Parexel and GlaxoSmithKline, where for over 10 years she led an international team of health outcomes scientists in the development of value strategies and evidence to enable reimbursement and access for GSK’s portfolio of medicines.  Before joining the pharmaceutical industry, she was a practicing general internist and health services researcher in the Department of Medicine at Duke University Medical Center, with an interest in disease management strategies, authoring over 40 publications.  Dr. Harpole holds an AB in Mathematics from Duke University, an MD from Duke University School of Medicine, and an MPH from Harvard School of Public Health. She also completed an internship in internal medicine and a fellowship in general internal medicine at Brigham and Women’s Hospital, Harvard Medical School. 


 

Terry Hisey

Deloitte, Senior Principal, Life Science & Health Care Practice

Terry Hisey is a senior principal in the Life Science and Health Care Practice for Deloitte. Mr. Hisey heads the firm's efforts with two global life science companies in medicines and medical technology.  Prior to this role, he spent eight years as the vice chairman of Deloitte leading its efforts in life sciences across all service areas of the firm.  Mr. Hisey's personal focus has been development and execution of strategies across a wide range of industry issues with a focus on implementation of sustainable change for competitive improvement. He has experience across the entire life sciences value chain including R&D, commercial, manufacturing and distribution, and key enabling areas.  Mr. Hisey has worked with industry executives in small- and large-molecule pharmaceuticals, medical technology companies as well as other key stakeholder groups across the LSHC ecosystem.


 

Ken Kaitin, PhD

Tufts Center for the Study of Drug Development, Professor and Director

Ken Kaitin is professor of medicine and director of the Tufts Center for the Study of Drug Development at Tufts University School of Medicine. He’s also advisory professor at Shanghai Medical College at Fudan University, and he serves on the faculty of the European Center for Pharmaceutical Medicine at the University of Basel. A former president of the Drug Information Association, Dr. Kaitin is editor-in-chief of Expert Review of Clinical Pharmacology, and a consultant to the US Department of Defense on bioterror countermeasures. In 2011, he received the Dr. Louis M. Sherwood Award, granted by the Academy of Pharmaceutical Physicians and Investigators. Dr. Kaitin received his BS from Cornell University and MS and PhD in Pharmacology from the University of Rochester.


 

Ranjini Prithviraj

DIA Publications, Senior Managing Editor/Associate Director

Dr. Ranjini Prithviraj is senior managing editor and associate director of publications at DIA, where she provides strategic thought leadership and delivers content that advances DIA’s mission through various media, including traditional journal publications. Prior to DIA, she was a managing editor at the American Chemical Society. 


 

Ellen Licking

EY, Senior Analyst, Global Life Sciences

Ellen Licking has been with EY since 2014 as a senior life sciences analyst supporting thought leadership creation and go-to-market conversations. Prior to joining EY, she covered the life sciences industry for nearly 20 years, first as a reporter at Businessweek, then as an executive writer/editor for the biopharmaceutical group at Windhover Information, and its acquirer Elsevier. At Elsevier, she was responsible for creating content for In Vivo and Start-Up magazines, as well as the annual Pharmaceutical Strategic Alliances meeting. From 2011 until June 2013, Ms. Licking worked as an analyst at the health care information-focused start-up Real Endpoints, developing thought leadership and marketing content on biopharmaceutical product reimbursement and product pricing. Currently, she helps EY leaders create compelling narratives about key topics facing the life sciences industry. She was also one of the key content developers for EY's Engaged Aging Summit, a cross-sector collaboration with the health sector, which positioned EY as shaping the debate around healthy aging. Ms. Licking holds a BA in Biochemistry from Swarthmore College and an MPhil in Biochemistry from Cambridge University.


 

Julie Locklear

Genesis Research, Managing Director 

Julie Locklear joined Genesis Research as managing director in January 2018.  Previously she was the vice president and head of health economics and outcomes research at EMD Serono, a business of Merck KGAA, Darmstadt, Germany. Her 20 years of experience stretches across all phases of development, both on the commercial and research sides of pharmaceutical organizations. Ms. Locklear has an Executive MS in Business Administration and a PhD in Pharmacy. Her publication record includes authorship of more than 30 peer-reviewed publications and over 60 peer-reviewed abstracts featured in peer-reviewed journals and presented at major scientific congresses.


 

Roger Longman

Real Endpoints, CEO

Roger Longman is CEO of Real Endpoints, a company focused on pharmaceutical reimbursement, and aiming to help both payers and product developers improve the value of pharmacotherapy.  Until November 2009, Longman was managing director, pharma at Elsevier Business Intelligence, a division of Reed Elsevier.  He has been involved with the health care industry for more than 25 years. From 1990 through 2008, Longman was co-CEO and managing director of Windhover Information, a company providing analysis and data around pharmaceutical and medical device business strategy through publications, databases and conferences.  Longman co-founded and built Windhover through internal development (with publications such as In Vivo, Start-Up and The RPM Report, several databases, including Strategic Transactions, and a series of senior-executive conferences), and through acquisition.  In 2008, Windhover was acquired by Reed Elsevier and merged with its FDC Reports division, creating Elsevier Business Intelligence. In 2010, Mr. Longman began working on Real Endpoints with Norman Selby, who had been Windhover’s chairman and lead investor. Mr. Longman often speaks at key industry events and he lectures regularly at several leading universities and co-directed the Wharton-Windhover pharmaceutical program at The Wharton School.  Mr. Longman completed his BA at Cornell University and an MA at the University of North Carolina at Chapel Hill.


 

Dan McIntyre

Publick House, Partner

Dan McIntyre is a principal of Publick House, a public affairs consultancy specializing in biopharmaceuticals and health care, and an inaugural member of Watershed Bridges, a micro-holding company of disciplines in health-care public relations, advertising, social/digital, patient behavior, public affairs, medical education, experiential marketing as well as the emerging field of patient intelligence. He founded Publick House in 2015, as an “encore” of a 40-year career in health policy and communication.  Prior to founding Publick House he served as SVP of corporate affairs for Biogen. He has also held the top global position in communications and/or public policy at Wyeth, Pharmacia and Bayer Pharmaceutical Division, and was managing director of the health-care practices at the global communication agencies Fleishman-Hillard and Hill+Knowlton Strategies. Mr. McIntyre started his career in hospital planning and reimbursement and has worked in this area since the advent of the first biotherapies in the 1980s.


 

Michael Ringel, PhD

BCG, Senior Partner and Global Topic Leader, Research & Product Development

Michael Ringel is a senior partner and managing director in BCG’s Boston office, and is BCG's global topic leader on research and product development. Mr. Ringel has worked for a range of biotech and pharmaceutical clients, with a focus on R&D strategy, operations and organization. Prior to joining the firm, he worked in academia, pursuing research in theoretical population dynamics and conducting field experiments in the Amazon basin near Manaus, Brazil. Mr. Ringel has a BA summa cum laude in Biology from Princeton University where he graduated number one in the department, a PhD in Biology from Imperial College (NSF and Fulbright Fellowships awarded) and a JD cum laude from Harvard Law School.


 

Kenneth Schultz, MD

Halozyme, Vice President of Innovation, Strategy & Business Development

Ken Schultz joined Halozyme in January 2015 as vice president of innovation, strategy and business development. Before that, Dr. Schultz held roles of increasing responsibility with Medtronic Diabetes, where he most recently served as chief of staff, strategy, and business development and was responsible for identifying and evaluating novel therapies to purchase, entering the type 2 diabetes market, pursuing comprehensive partnerships, creating new service line strategies and pursuing external investments. Prior to his role at Medtronic Diabetes, Dr. Schultz worked at McKinsey & Co. from 2007 to 2012, where he provided consultative services to a range of global organizations across the medical device and pharmaceutical sectors. He received his MD from Texas Tech University, an MBA from IMD in Switzerland and a bachelor’s degree from Texas A&M University. Dr. Schultz began his career as a practicing physician. From 1999 to 2005, he worked in various positions including vice chairman of emergency medicine with EMCare Physicians.


 

Jack Wong

Baxter Healthcare, Head of Regulatory Affairs, APAC

Jack Wong is currently RA head, APAC of Baxter Healthcare. He has over 20 years of regulatory, clinical trial and pharmacovigilence experience in Asia with expertise in medical devices, pharmaceuticals, nutritional, consumer health care and biological products. Externally, he plays a leading role among all the regional regulatory professionals in AHWP (Asian Harmonization Working Party), and has been invited to provide regulatory training to local universities and industry organizations. Mr. Wong is also very active in ASEAN, APEC, ISO and WHO projects. He developed the First Asia Regulatory Affairs Certificate course in 2007, which has more than 1,500 alumni. He is also the founder (2010) of ARPA (Asia Regulatory Professional Association), which has more than 1,600 members and Asia GRP (Good Regulatory Practice) Research Center. Mr. Wong is the author of the Handbook of Medical Device Regulatory Affairs in Asia, which was published in May 2013.


 

Nadim Yared

CVRx, President & CEO

Nadim Yared is the president and chief executive officer of CVRx. Mr. Yared previously served as VP and general manager of Medtronic Navigation, the leading supplier of integrated image-guided surgery products, from 2002 to 2006. He also worked at GE Medical for 10 years, where he held the position of VP of global marketing for OEC Medical Systems and VP and general manager of GE’s European X-ray business based in Paris. Yared has an engineering degree from Ecole Nationale Supérieure des Télécommunications, and an MBA from INSEAD, France. He recently served as the chairman of the AdvaMed Accel board and he is currently the chairman of the AdvaMed board of directors. This is the first time that the CEO of a small company has become chairman of the AdvaMed board of directors in the 41 years of the existence of the organization. Mr. Yared was named one of the “100 people to know in 2017,” by Minneapolis’ Twin Cities Business magazine.


 

Sara Jane Demy

Demy Colton, CEO

Sara Jane Demy established Demy-Colton in 2008 to develop high value-added events and help reposition existing events in the life sciences industry. Her impressive background in supporting biotech’s growth includes being the founder of Biotech Showcase and the Biotech CEO Summits. In addition, Sara was previously vice president, business development & investor relations, and head of the New York Office for the Biotechnology Industry Organization (BIO). She understood the problems facing biotech companies and developed solutions to help advance the sector.


 

Annalisa Jenkins

PlaqueTec, CEO

Dr. Annalisa Jenkins is a life sciences thought leader with over 25 years of biopharmaceutical industry experience. Prior to joining PlaqueTec as CEO in November 2017, Dr. Jenkins served as president and CEO of Dimension Therapeutics, a leading gene therapy company that was acquired by Ultragenyx in November 2017. Prior leadership roles have included the head of global research and development and executive vice president of global development and medical at Merck Serono, and several senior positions at Bristol Myers-Squibb over 15 years – including serving as senior vice president and head of global medical affairs. Earlier in her career, Dr. Jenkins was a medical officer in the British Royal Navy during the Gulf Conflict, achieving the rank of surgeon lieutenant commander. Dr. Jenkins is a board member of several growing companies, including Ardelyx, Inc., iOX Therapeutics Limited, Thrombolytic Strategies Incorporated, PhESi, Oncimmune, AVROBIO, COMPASS Pathways, AOBiome, Cocoon Biotech Inc. (non-executive chair), Cellmedica (non-executive chair), Vium, Inc. (executive chair), and Silence Therapeutics (executive chair).  She also is a committee member of the Science Board to the US Food & Drug Administration, and serves on the board of the Center for Talent Innovation in the UK. Dr. Jenkins graduated with a degree in medicine from St. Bartholomew’s Hospital in the University of London and subsequently trained in cardiovascular medicine in the U.K. National Health Service.


 

Barbara Freischem

EBE - European Biopharmaceutical Enterprises, Executive Director

Barbara Freischem is executive director of the European Biopharmaceutical Enterprises, EBE – a specialised group of EFPIA, the European association for the pharmaceutical industry. EBE looks after the needs of innovative biologics manufacturers of all sizes in the EU. Focus activities center on ensuring a positive regulatory environment for biopharmaceuticals, in particular cell and gene therapies and products using the personalised medicine approach, as well as funding mechanisms for small and medium-sized enterprises. Ms Freischem, a qualified veterinarian, has significant experience both on the side of regulatory authorities as well as of the regulated industry in a variety of technical and leadership roles.

UsernamePublicRestriction

Register

Advertisement